• 1.
    Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365: 217223.
  • 2.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics 2012 update; a report from the American Heart Association. Circulation. 2012;125:e12e230.
  • 3.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 4.
    Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466472.
  • 5.
    Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control—continued disparities in adults: United States, 2005–2006. NCHS Data Brief No. 3. Hyattsville, MD: National Center for Health Statistics; 2008.
  • 6.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:20432050.
  • 7.
    Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52: 17491757.
  • 8.
    Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:19992010.
  • 9.
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:27612788.
  • 10.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:14621536.
  • 11.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:10761080.
  • 12.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510e526.
  • 13.
    Esler M, Jennings G, Korner P, et al. Total and organ-specific noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens A. 1984:6:507521.
  • 14.
    Esler M, Jennings G, Korner P, et al. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:320.
  • 15.
    Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:17471762.
  • 16.
    Narkiewicz K, Pesek CA, Kato M, et al. Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension. 1998;32:10391043.
  • 17.
    Vollenweider P, Tappy L, Randin D, et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92:147154.
  • 18.
    Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:30973101.
  • 19.
    Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909920.
  • 20.
    Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106: 19741979.
  • 21.
    DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245R253.
  • 22.
    Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension. Results in 1,266 cases. JAMA. 1953;152:15011504.
  • 23.
    Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension. A review of 74 patients. Br J Surg. 1954;41:382392.
  • 24.
    Smithwick RH. Surgical treatment of hypertension. Am J Med. 1948:4:744759.
  • 25.
    Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217222.
  • 26.
    Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:19121918.
  • 27.
    Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009; 361:932934.
  • 28.
    Krum H, Sobotka P, Mahfoud F, et al. Device-Based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209215.
  • 29.
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.
  • 30.
    Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911917.
  • 31.
    Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:19031909.
  • 32.
    Schlaich MP, Krum H, Sobotka PA, et al. Renal denervation and hypertension. Am J Hypertension. 2011;24:635642.
  • 33.
    Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:18821888.
  • 34.
    Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100:10491057.
  • 35.
    Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123: 19401946.
  • 36.
    Schlaich MP, Straznicky N, Grima M, et al Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991996.